Mopetia (Paliperidone)

Paliperidone, the active ingredient in Mopetia, is an atypical antipsychotic presented as an intramuscular injection for intramuscular use. It is indicated for the treatment of schizophrenia and schizoaffective disorder in adult patients. The formulation is designed for rapid onset of action and is administered by a healthcare professional.

GNH USA supplies Mopetia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our global distribution network ensures consistent quality and regulatory compliance across all markets, with reliable delivery timelines.

Paliperidone is an atypical antipsychotic used to manage psychotic disorders.

Schizophrenia: reduces positive and negative symptoms and helps prevent relapse. Schizoaffective disorder: stabilises mood and psychotic symptoms. Acute exacerbation of schizophrenia: provides rapid symptom relief during flare‑ups.

Paliperidone may cause a range of adverse reactions.

Common Side Effects: - Weight gain: increase in body mass. - Somnolence: drowsiness or fatigue. - Extrapyramidal symptoms: tremor, rigidity, or akathisia. - Hyperprolactinemia: elevated prolactin levels causing menstrual changes.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: persistent involuntary movements. - Seizures: risk of convulsive episodes.

When using Mopetia, clinicians should observe several safety measures.

Monitor metabolic parameters: check weight, glucose, and lipid levels regularly. Assess for movement disorders: watch for signs of extrapyramidal symptoms or tardive dyskinesia. Evaluate cardiovascular status: monitor blood pressure and heart rate. Use caution in patients with renal impairment: dose may need adjustment. Avoid abrupt discontinuation: taper under medical supervision to prevent withdrawal. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Paliperidone can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole): may increase paliperidone levels. - CNS depressants (e.g., benzodiazepines): additive sedation risk. - Antihypertensives: may enhance hypotensive effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Anticholinergic agents: may mask extrapyramidal symptoms. - QT‑prolonging drugs: increase risk of cardiac arrhythmia.